Xalkori (Crizotinib), for Certain Non-Small Cell Lung Cancers, Gets FDA New Drug Application Approval
Lung Cancer, News
Pfizer’s supplemental new drug application for Xalkori (crizotinib) has been approved by the U.S. FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC). The drug is also ... Read more